SCHEMBL12679583

SCHEMBL12679583

Cc1cc(C(=O)Nc2ccc(Cl)c(-c3cnc4ccccc4n3)c2)c(C)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
HPGD P15428 1/20 0.51
MAPT P10636 5/20 0.48
THRB P10828 1/20 0.48
GAA P10253 1/20 0.47
PTGES O14684 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12679587 0.88 PTGES (0.49) NPC1RAB9AMAPTTHRBGAA
SCHEMBL12679567 0.86 NPC1 (0.55) NPC1RAB9AHPGDMAPTTHRB
SCHEMBL9965058 0.84 PKM (0.52) NPC1RAB9APKMMEN1KMT2A
SCHEMBL12681298 0.81 KMT2A (0.48) NPC1RAB9AMAPTGAAMEN1
SCHEMBL12679563 0.81 LMNA (0.52) NPC1RAB9AMAPTTHRBGAA
SCHEMBL12679566 0.81 HTT (0.48) NPC1RAB9AMEN1KMT2ACYP1A2
SCHEMBL12679606 0.81 KMT2A (0.65) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL12681346 0.81 RAB9A (0.64) NPC1RAB9AMAPTGAASMN1; SMN2
SCHEMBL12679593 0.81 ALDH1A1 (0.51) NPC1RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL12679590 0.81 KMT2A (0.47) NPC1RAB9AHPGDMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273743-B2 N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies CURIS, INC. (US) 2012-09-25 US disclosed
US-8273743-B2 N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies CURIS, INC. (US) 2012-09-25 US disclosed
US-20080261989-A1 Quinoxaline Inhibitors of the Hedgehog Signalling GENENTECH, INC. 2008-10-23 US disclosed
US-20080261989-A1 Quinoxaline Inhibitors of the Hedgehog Signalling GENENTECH, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261989-A1 Quinoxaline Inhibitors of the Hedgehog Signalling SHH, NR4A2, NR4A3 NPC1 2120/4885RAB9A 2425/4885HPGD 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.